Absci to Host KOL Seminar on ABS-201 Androgenetic Alopecia Program on December 11, 2025; Announces Accelerated Initiation of Phase 1/2a Trial
Provided By GlobeNewswire
Last update: Oct 15, 2025
Webinar on December 11 to feature leading KOLs in dermatology and hair loss alongside Absci leadership
Phase 1/2a trial now expected to begin in December 2025, ahead of prior guidance
Read more at globenewswire.comNASDAQ:ABSI (11/25/2025, 1:47:04 PM)
2.975
+0.02 (+0.51%)
Find more stocks in the Stock Screener
ABSI Latest News and Analysis
